2025 was a landmark year for scientific innovation and digital transformation across the life sciences. From the first personalized CRISPR-based therapy for a rare disease to major advances in synthetic chemistry and molecular design, the pace of discovery accelerated across biotechnology, pharmaceuticals, and materials science. At the same time, artificial intelligence became increasingly embedded in research and development workflows, reshaping how scientists design experiments, analyze results, and make data-driven decisions.
For Revvity Signals, 2025 represented a year of meaningful progress and platform evolution. Building on momentum from previous years, the company focused on a central goal: unifying scientific data, tools, and collaboration across the entire discovery lifecycle. Through new platform capabilities, expanded AI-driven features, and stronger engagement with the scientific community, Revvity Signals continued to strengthen the digital infrastructure supporting modern research environments.
Celebrating 40 Years of ChemDraw
One of the most significant milestones of the year was the 40th anniversary of ChemDraw, one of the most influential tools in modern chemistry. Since its introduction in 1985, ChemDraw has transformed the way scientists communicate molecular structures. What once required careful manual drawing can now be created instantly using standardized digital formats, making chemical information easier to visualize, share, and interpret.
Over four decades, ChemDraw has evolved far beyond a simple molecular drawing tool. Today, it integrates capabilities such as name-to-structure conversion, spectral prediction, 3D conformational modeling, and cloud-enabled collaboration through Signals ChemDraw. These advancements have made it an essential resource not only for chemists but also for fields such as cheminformatics, drug discovery, and AI-driven molecular design.
Throughout 2025, Revvity Signals highlighted this legacy through the ChemDraw Connect series, showcasing new features, scientific applications, and community contributions that continue to shape the future of chemical research.
Unifying Data to Accelerate Discovery
As artificial intelligence and advanced analytics become foundational technologies in modern science, data interoperability has become a critical requirement for research organizations. Fragmented datasets and disconnected workflows often slow down discovery and limit the impact of analytical tools.
To address this challenge, Revvity Signals introduced Signals One™, a cloud-native platform designed to unify scientific data across the entire “Design–Make–Test–Decide” lifecycle. Signals One standardizes experimental data, enables advanced analysis such as curve fitting and group comparisons, and facilitates seamless collaboration between research teams working across disciplines.
By creating a unified environment for chemistry, biology, materials science, and formulation research, Signals One helps organizations generate analytics-ready data that can support machine learning, AI-assisted discovery, and more efficient R&D decision-making.
Expanding the Scientific Software Ecosystem
Continuous innovation remained a core focus for Revvity Signals in 2025. The company announced plans to integrate ACD/Labs technologies into the Signals platform, creating a more unified SaaS ecosystem that connects molecular design, analytical chemistry, and manufacturing quality control.
This integration aims to provide scientists with an end-to-end environment where experimental data, analytical insights, and production workflows can coexist within a single digital framework.
In addition to these integrations, Revvity Signals previewed several new solutions designed to support evolving research needs.
Signals BioDesign, an enterprise SaaS platform for molecular biology workflows, focuses on streamlining cloning processes and high-throughput plasmid modeling. By integrating directly with other Signals tools, BioDesign helps research teams collaborate more effectively on large-molecule design projects.
Another upcoming solution, Signals LabGistics, is designed to simplify workflow management across the drug development lifecycle. The platform allows teams to plan experiments, track tasks, and monitor progress while ensuring that scientific data flows seamlessly between research and production stages.
Advancing AI-Powered Scientific Discovery
Artificial intelligence remained one of the defining themes of scientific innovation in 2025. Within the Revvity Signals ecosystem, AI-powered features were introduced to help scientists analyze information faster and extract deeper insights from complex datasets.
For example, semantic search and text-to-image extraction capabilities within Signals One allow researchers to quickly identify relevant information within large experimental records, improving documentation and accelerating knowledge discovery.
Another significant development was the announcement of Signals Xynthetica™, a Models-as-a-Service AI offering designed to support AI-augmented molecular and materials design. By combining predictive modeling, in-silico generation, and experimental validation within a single governed environment, Xynthetica enables research teams to iteratively design and refine candidate molecules with greater confidence.
These innovations demonstrate how AI can support—not replace—scientific expertise by helping researchers navigate increasingly complex data landscapes.
Strengthening Customer Collaboration
Customer collaboration played a central role in shaping the 2025 product roadmap. Revvity Signals continued expanding its Ideas Portal, giving users a direct channel to propose features and improvements for the platform.
During the year, the company implemented 17% of submitted customer ideas, significantly higher than the industry average. This reflects a strong commitment to incorporating real-world feedback into product development and ensuring that new capabilities address the needs of scientific teams.
In addition to digital engagement, Revvity Signals hosted several global events designed to bring together researchers, IT leaders, and scientific software experts.
Events such as NEXUS Europe 2025, Japan NEXUS, and the Signals Innovator gatherings provided opportunities for technical discussions, product demonstrations, and collaborative exploration of emerging trends in scientific informatics.
Transforming Clinical Data Management
In the clinical research space, the introduction of Signals Clinical marked another major step forward. As a cloud-native platform, Signals Clinical enables teams to manage study data in real time, improving transparency and accelerating analytics across clinical trials.
One of the most notable innovations was the launch of the Custom Listings Generator, an AI-powered feature that allows researchers to generate tailored clinical data listings without programming knowledge. This functionality improves reproducibility, ensures compliance, and significantly reduces the time required to prepare regulatory documentation.
Combined with new approaches to knowledge integration and retrieval-augmented generation, Signals Clinical is helping organizations streamline clinical research while maintaining strong scientific governance.
Looking Ahead to 2026
As Revvity Signals moves into 2026, the focus remains on strengthening the connections between data, digital tools, and the global scientific community. The company plans to expand AI capabilities across its platforms, deepen partnerships with technology providers, and continue supporting researchers through collaborative initiatives and educational resources.
By building a unified environment where experimental data, analytics, and collaboration tools coexist, Revvity Signals aims to empower scientists to move discoveries from concept to application more efficiently than ever before.
Ultimately, the progress achieved in 2025 reflects a broader transformation across the scientific landscape: a future where integrated data ecosystems, AI-powered insights, and collaborative research platforms accelerate innovation and enable breakthroughs that improve human health and global well-being.